Infrequent
Regeneron Leads $66M Series B for Actio Biosciences’ Rare Disease Therapeutics
Regeneron; Actio Biosciences; rare diseases; Series B financing; KCNT1 inhibitor; TRPV4 inhibitor; ABS-1230; ABS-0871; Charcot-Marie-Tooth disease; epilepsy; orphan drug; clinical trials
Beyond Theory: Real-World AI Wins in Life Science R&D – Faster & Smarter
AI in life sciences; R&D efficiency; drug discovery; clinical trials; pharma innovation; 2025 AI trends; cost reduction; rare diseases
Senate Drops Orphan Cures Act from Trump’s Tax Bill, Dealing Setback to Biopharma
Orphan Cures Act; orphan drugs; Trump tax bill; biopharma; Senate; IRA price negotiations; rare diseases; Big Beautiful Bill; healthcare legislation; reconciliation bill
Recursion Pharmaceuticals Lays Off 20% of Staff Amid Pipeline Cutbacks
Recursion Pharmaceuticals; layoffs; pipeline cutbacks; biotech; workforce reduction; restructuring; rare diseases; oncology
EMA Identifies Very Rare Eye Condition as Side Effect of Semaglutide
EMA; semaglutide; rare side effect; NAION; vision loss; Ozempic; Wegovy; Rybelsus
Sarepta’s rAAVrh74 Viral Vector Receives FDA Platform Technology Designation for Gene Therapy
Sarepta Therapeutics; FDA; platform technology designation; rAAVrh74 viral vector; gene therapy; SRP-9003; limb-girdle muscular dystrophy; rare diseases
Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion, Expanding Immunology Focus
Sanofi; Blueprint Medicines; acquisition; immunology; systemic mastocytosis; Ayvakit; elenestinib; rare diseases; biopharma; pipeline
FDA Rejects Stealth BioTherapeutics’ Rare Disease Drug but Leaves Door Open for Accelerated Approval
FDA rejection; Stealth BioTherapeutics; elamipretide; Barth syndrome; rare disease; accelerated approval; muscle strength endpoint; phase 2 trial; regulatory delay
Applied Therapeutics’ Rare Disease Drug Fails Another Phase 3 Trial After FDA Rejection
Applied Therapeutics; govorestat; rare disease; phase 3 failure; FDA rejection; classic galactosemia; aldose reductase inhibitor; clinical trial conduct; FDA warning letter
BioMarin Acquires Inozyme Pharma for $270M, Gaining Phase 3 Rare Disease Therapy
BioMarin; Inozyme Pharma; acquisition; rare disease; INZ-701; ENPP1 Deficiency; enzyme replacement therapy; Phase 3 clinical trial